학술논문
Glofitamab, a Novel, Bivalent CD20-targeting t-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-Cell Lymphoma: A phase i trial
Document Type
Article
Author
Hutchings, M.; Morschhauser, F.; Iacoboni, G.; Carlo-Stella, C.; Offner, F.C.; Sureda, A.; Salles, G.; Martinez-Lopez, J.; Crump, M.; Thomas, D.N.; Morcos, P.N.; Ferlini, C.; Broske, A.; Moore, T.; Weisser, M.; Belousov, A.; Bacac, M.; Umaña, P.; Dimier, N.; Carlile, D.J.; Lundberg, L.; Perez-Callejo, D.; Dickinson, M.J.
Source
In: Journal of Clinical Oncology . (Journal of Clinical Oncology, 20 June 2021, 39(18):1959-1970)
Subject
Language
English
ISSN
15277755
0732183X
0732183X